• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

曾发生严重输液反应的患者使用英夫利昔单抗成功进行再次治疗。

Successful retreatment with infliximab in patients with prior severe infusion reactions.

作者信息

Uthman Imad, Touma Zahi, El-Sayyad Jinane, Zaitoun Fares

机构信息

Division of Rheumatology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

出版信息

Clin Rheumatol. 2006 Jul;25(4):540-1. doi: 10.1007/s10067-005-0029-9. Epub 2005 Oct 7.

DOI:10.1007/s10067-005-0029-9
PMID:16211336
Abstract

Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.

摘要

再次输注抗肿瘤坏死因子-α嵌合单克隆抗体英夫利昔单抗时，可能会出现严重的输注反应（IR）。我们报告了两例类风湿关节炎患者的病例，这两名患者既往输注英夫利昔单抗时曾发生严重急性IR，随后通过联合使用H1和H2受体阻滞剂、氢化可的松和苯海拉明进行预防性治疗，成功完成了输注。

相似文献

1
Successful retreatment with infliximab in patients with prior severe infusion reactions.曾发生严重输液反应的患者使用英夫利昔单抗成功进行再次治疗。
Clin Rheumatol. 2006 Jul;25(4):540-1. doi: 10.1007/s10067-005-0029-9. Epub 2005 Oct 7.
2
Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.临床实践中类风湿关节炎患者对英夫利昔单抗的输液相关反应：与剂量、抗组胺药预处理及输液次数的关系
J Rheumatol. 2004 Oct;31(10):1912-7.
3
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.英夫利昔单抗用于克罗恩病成人和儿童的再治疗：迟发性严重全身反应发生的危险因素
Am J Gastroenterol. 2002 Jun;97(6):1408-14. doi: 10.1111/j.1572-0241.2002.05784.x.
4
Premedication prevents infusion reactions and improves retention rate during infliximab treatment.预处理可预防英夫利昔单抗治疗期间的输注反应并提高保留率。
Clin Rheumatol. 2016 Nov;35(11):2841-2845. doi: 10.1007/s10067-016-3351-5. Epub 2016 Jul 19.
5
[Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].[186例意大利类风湿关节炎患者英夫利昔单抗输注反应的发生率及处理：帕多瓦经验]
Reumatismo. 2005 Jan-Mar;57(1):44-51. doi: 10.4081/reumatismo.2005.44.
6
Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis.有或无倍他米松预处理的英夫利昔单抗输注在活动性类风湿关节炎患者中的耐受性研究。
Ann Rheum Dis. 2005 Nov;64(11):1647-9. doi: 10.1136/ard.2005.037499.
7
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.一项开放标签研究，旨在评估类风湿关节炎患者中英夫利昔单抗的安全性及临床获益起效时间。
J Rheumatol. 2002 Apr;29(4):667-77.
8
Predictors of infusion reactions during infliximab treatment in patients with arthritis.关节炎患者英夫利昔单抗治疗期间输液反应的预测因素。
Arthritis Res Ther. 2006;8(4):R131. doi: 10.1186/ar2020.
9
Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.在炎症性肠病患者中预防急性英夫利昔单抗输注反应的预处理用药：一项单中心队列研究。
Inflamm Bowel Dis. 2017 Oct;23(10):1882-1889. doi: 10.1097/MIB.0000000000001189.
10
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.用于预防紫杉醇相关过敏反应的短疗程静脉用药方案
Ann Oncol. 1997 Jun;8(6):611-4. doi: 10.1023/a:1008207025430.

引用本文的文献

1
The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.生物疗法在类风湿关节炎以外的难治性风湿性疾病中的应用：黎巴嫩一家三级医疗中心的经验。
Rheumatol Int. 2009 Aug;29(10):1255-7. doi: 10.1007/s00296-008-0816-0. Epub 2008 Dec 4.

本文引用的文献

1
Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.临床实践中类风湿关节炎患者对英夫利昔单抗的输液相关反应：与剂量、抗组胺药预处理及输液次数的关系
J Rheumatol. 2004 Oct;31(10):1912-7.
2
Safety overview of new disease-modifying antirheumatic drugs.新型抗风湿药物的安全性概述
Rheum Dis Clin North Am. 2004 May;30(2):237-55, v. doi: 10.1016/j.rdc.2004.02.003.
3
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
英夫利昔单抗在克罗恩病患者中的安全性概况：梅奥诊所500例患者的经验
Gastroenterology. 2004 Jan;126(1):19-31. doi: 10.1053/j.gastro.2003.10.047.
4
The histamine-cytokine network in allergic inflammation.
J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S83-8. doi: 10.1016/s0091-6749(03)01881-5.
5
The incidence and management of infusion reactions to infliximab: a large center experience.英夫利昔单抗输注反应的发生率及处理：大型中心经验
Am J Gastroenterol. 2003 Jun;98(6):1315-24. doi: 10.1111/j.1572-0241.2003.07457.x.
6
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.英夫利昔单抗用于克罗恩病成人和儿童的再治疗：迟发性严重全身反应发生的危险因素
Am J Gastroenterol. 2002 Jun;97(6):1408-14. doi: 10.1111/j.1572-0241.2002.05784.x.
7
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.英夫利昔单抗维持治疗克罗恩病：ACCENT I随机试验
Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4.
8
Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists.使用H1和H2拮抗剂联合治疗的急性过敏综合征患者的预后得到改善。
Ann Emerg Med. 2000 Nov;36(5):462-8. doi: 10.1067/mem.2000.109445.
9
Long term safety of infliximab.英夫利昔单抗的长期安全性。
Can J Gastroenterol. 2000 Sep;14 Suppl C:29C-32C. doi: 10.1155/2000/698523.